Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma
Information source: Medical College of Wisconsin
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hepatocellular Carcinoma; Hepatocellular Cancer; Hepatoma; Liver Cancer
Intervention: Sorafenib (Drug); Conventional fractionation (2 Gy per day) external beam radiation therapy (Radiation)
Phase: Phase 1
Status: Withdrawn
Sponsored by: Medical College of Wisconsin Official(s) and/or principal investigator(s): Beth A. Erickson-Wittmann, M.D., Principal Investigator, Affiliation: Medical College of Wisconsin
Summary
To determine the maximum tolerated radiation dose with concurrent sorafenib for unresectable
hepatocellular carcinoma that has not responded to transarterial chemoembolization.
Clinical Details
Official title: Phase I Study of Radiation Therapy With Concurrent Sorafenib for Hepatocellular Carcinoma Not Responding to Transarterial Chemoembolization
Study design: Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Maximum Tolerated Dose
Secondary outcome: Radiographic ResponsePatterns of Failure Progression Free Survival Overall Survival Health Related Quality of Life
Detailed description:
In patients with unresectable hepatocellular carcinoma (HCC), transarterial
chemoembolization (TACE) is first line therapy. Non-responders to TACE (i. e. stable or
progressive disease) represent a poor prognosis population with limited options. Sorafenib
is indicated for first line salvage therapy, however it only improves survival 2-3 months
and just has a 2-3% response rate. Thus, sorafenib is merely a cytostatic agent that delays
progression and does not cytoreduce disease.
Radiation therapy (RT) is a non-invasive treatment that can cytoreduce HCC with minimal
morbidity using modern techniques. A meta-analysis and multiple retrospective series suggest
TACE + RT improve survival when compared to TACE alone. Higher RT doses are similarly
associated with increased survival due to improved local control. Paradoxically, some series
suggest that RT can induce vascular endothelial growth factor (VEGF) expression which may
stimulate HCC.
Pre-clinical data suggest that combining RT with concurrent sorafenib (a VEGF inhibitor)
improves tumor control. However, clinical data is limited to case reports and safety has not
been well characterized. Prior to determining if this combination can improve control of HCC
in this poor prognosis population, the optimal radiation dose with concurrent sorafenib must
be determined by a phase I dose escalation trial.
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Radiographic or histologic diagnosis of hepatocellular carcinoma (HCC).
- Maximum of 3 HCC lesions within the liver.
- No evidence of lymphadenopathy or metastatic disease per either CT or PET.
- Prior transarterial chemo-embolization (TACE) at least 28 days prior to initiation of
protocol therapy.
- Evidence of either progressive disease or stable disease following TACE.
- Child Pugh Class A (score 5-6) or B (score 7).
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1 (or Karnofsky ≥70%).
- Normal organ and marrow function (platelets >60,000/mc; hemoglobin ≥8. 5 g/dL;
international normalized ratio (INR) ≤2. 3; albumin ≥2. 8 g/dL; total bilirubin ≤3
mg/dL; aspartate aminotransferase (AST) / alanine aminotransferase (ALT) <5x upper
limit of normal; creatinine ≤1. 5x upper limit of normal).
- Negative human immunodeficiency virus serology.
- Negative pregnancy test for women of child bearing age.
- Ability to understand and willingness to sign a written informed consent document.
Exclusion Criteria:
- Less than 800 cc of normal liver.
- Child Pugh Class B (score 8-9) or C (score 10-15).
- Acute/active hepatitis B infection.
- Prior systemic chemotherapy or abdominal radiation therapy.
- Portal venous (main, primary right, or primary left trunks) or inferior vena cava
thrombosis.
- Prior malignancy within 5 years of enrollment except for non-melanoma skin cancer.
- Prior history of myocardial infarction, cerebrovascular accident, or esophageal
variceal bleed in the last 6 months.
- Pre-existing heart failure with either a clinical classification of New York Heart
Association Class III or IV or cardiac ejection fraction of <45%.
- Systolic blood pressure > 160 mmHg or diastolic pressure > 100 mmHg despite optimal
medical management.
- Pulmonary hemorrhage or other serious bleeding event (grade 2+) within 4 weeks
initiation of protocol therapy.
- Prior history of scleroderma or active systemic lupus erythematosus.
Locations and Contacts
Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin 53226, United States
Additional Information
Related publications: Chung YL, Jian JJ, Cheng SH, Tsai SY, Chuang VP, Soong T, Lin YM, Horng CF. Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma. Clin Cancer Res. 2006 May 1;12(9):2706-15. Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, McDonough J, Cerniglia G, Rajendran RR, Gupta A, Rustgi AK, Diehl JA, Smith CD, Flaherty KT, El-Deiry WS. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res. 2007 Oct 1;67(19):9443-54. Ren ZG, Zhao JD, Gu K, Chen Z, Lin JH, Xu ZY, Hu WG, Zhou ZH, Liu LM, Jiang GL. Three-dimensional conformal radiation therapy and intensity-modulated radiation therapy combined with transcatheter arterial chemoembolization for locally advanced hepatocellular carcinoma: an irradiation dose escalation study. Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):496-502. doi: 10.1016/j.ijrobp.2009.10.070. Epub 2010 Apr 24.
Starting date: June 2012
Last updated: September 4, 2013
|